HNN3.0
Register
Register
Register

Project cooperationUpdated on 5 February 2026

Looking for Consortium: Asst. Professor Md Sema Güler

Project Manager at Ankara Medipol University

Ankara, Türkiye

About

Aşağıda, paylaşılan bilgilerin akademik terminolojiye ve uluslararası proje konsorsiyum formatlarına uygun, yüksek nitelikli İngilizce çevirisi yer almaktadır:

1. PERSONAL & INSTITUTIONAL IDENTIFICATION

  • Current Position: Assistant Professor of Pharmacology

  • Nationality: Turkish (Eligible Associated Country Participant)

  • ORCID: 0000-0003-4975-3831

2. PROFESSIONAL SUMMARY & RESEARCH VISION

As an academician specializing in clinical pharmacology, I focus on the rational use of medicines and public health-oriented pharmacotherapy strategies. My professional background is established upon extensive multidisciplinary clinical experience, spanning a broad spectrum from primary care to tertiary centers, including intensive care and hematopoietic stem cell transplantation units. My core competencies encompass healthcare monitoring and evaluation, pharmacovigilance, adverse drug reaction (ADR) surveillance, and the development of evidence-based prescribing models.

Research Goal: Within the scope of the project, I aim to serve as the "Clinical & Public Health Lead," ensuring the seamless integration of clinical pharmacology principles into routine healthcare delivery. My primary focus involves enhancing therapeutic efficacy, minimizing preventable medication-related harm, and developing sustainable, patient-centered pharmacotherapy strategies.

3. METHODOLOGICAL EXPERTISE & RESEARCH FOCUS

My research activities prioritize the translation of clinical data into scientific projects through a translational medicine perspective:

  • Clinical Pharmacotherapy Management: Evaluation of pharmacological treatment strategies within the framework of evidence-based medicine and the integrated interpretation of patient findings with laboratory and imaging data.

  • Drug Safety & Monitoring: Monitoring of adverse effects, assessment of treatment adherence, and conduction of population-level drug utilization analyses.

  • Translational Approach: Formulating research questions derived from diagnostic and therapeutic challenges encountered in clinical practice and converting real-world data into scientific outputs.

  • Educational Leadership: Management of theoretical and practical pharmacology education for medical students and healthcare professionals.

4. CLINICAL DOMAINS OF APPLICATION

  • Oncology & Hematology: Management of chemotherapy-related adverse effects, supportive pharmacotherapy, and optimization of complex treatment protocols in hematopoietic stem cell transplantation.

  • Primary Care & Public Health: Rational Use of Medicines (RUM) programs, pharmacovigilance activities in community health centers, and drug utilization dynamics in emergency and intensive care settings.

5. PROJECT EXPERIENCE & PROPOSED ROLE

Throughout my academic career, I have served as a researcher in various translational studies focusing on pharmacovigilance and drug utilization evaluation within national healthcare systems. My doctoral-level expertise in pharmacogenetics and clinical pharmacology is evidenced by peer-reviewed international publications.

Proposed Role in Consortium: As the "Clinical & Public Health Lead," I am prepared to contribute by providing clinical pharmacology expertise to the study design, leading work packages focused on medication safety and rational use, and ensuring the translational applicability of project outputs.

Infrastructure & Data Capacity: Through established collaborations with university hospitals and public health institutions, I maintain access to extensive clinical infrastructures and datasets. My experience in ethical approval processes, patient data governance, and clinical research regulations will provide significant added value in integrating multicenter data and generating real-world evidence (RWE).

Topic

  • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
  • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-03: Building public trust and outreach in the life sciences
  • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health
  • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-05: Support for a multilateral initiative on climate change and health research
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

Type

  • Partner seeks Consortium/Coordinator

Organisation

Ankara Medipol University

University

Ankara, Türkiye

Similar opportunities

  • Project cooperation

    Pharmacists’ Association as a Partner for Public Health, Patient Education and Community-Based Research

    • Partner seeks Consortium/Coordinator
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-03: Building public trust and outreach in the life sciences
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-05: Support for a multilateral initiative on climate change and health research
    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-04: Towards climate resilient, prepared and carbon neutral populations and healthcare systems
    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Pharmaceutical association Srbija

    NGO at FNP

    Niš, Serbia

  • Project cooperation

    HealthTech expertise + Nursing (ICU, Cardiology, Public Health) + Data science + Policy seeks project cooperation

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Cidália Eusébio

    Consultant at Innovhygia Ltd

    London, United Kingdom

  • Project cooperation

    Hospital-based Translational Research & Clinical Trials Partner

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Iacopo Megna

    Clinical Project Manager - Grant Officer at University Hospital SS Antonio e Biagio e C. Arrigo

    Alessandria, Italy